Human Reproduction, Vol. 11, No. 1, pp. 55-60, 1996
© 1996 European Society of Human Reproduction and Embryology
research-article |
Short term pituitary desensitization: effects of different doses of the gonadotrophin-releasing hormone agonist triptorelin
Division of Reproductive Endocrinology and Fertility, Institute for Endocrinology, Reproduction and Metabolism, Vrije Universiteit Amsterdam, The Netherlands 1Ferring AB, Malmö Sweden
Correspondence: 2To whom correspondence should be addressed at: Department of Obstetrics and Gynaecology, Division of Fertility and Endocrinology, Academic Hospital of the University of Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands
Gonadotrophin-releasing hormone agonists (GnRHa) are used to prevent inadequate luteinizing hormone (LH) surges during ovarian stimulation in in-vitro fertilization (IVF). Dose studies for optimal dose assessment are lacking and unfavourable effects of the agonist on granulosa function and oocyte quality have been suggested. This double-blind randomized study was undertaken to assess the effect of four different doses of triptorelin on the degree of desensitization of the pituitary, and the recovery time of pituitary function after withdrawal of the agonist. Sixty-six regularly cycling women were allocated to a treatment group (n = 32) and a control group (n = 34). To assess the degree of pituitary desensitization and restoration in the treatment group, gonadotrophin releasing hormone (GnRH) challenges (100 µg, i.v.) were performed during treatment (day 17), and 2, 4 and 6 days after discontinuation of treatment At the same time blood samples for oestradiol and triptorelin concentrations were drawn. In the control group a GnRH test was performed on day 2 of the menstrual cycle. Both pituitary desensitization during and pituitary recovery after agonist treatment, expressed as the LH response to exogenous GnRH, appeared to be dose dependent As the use of reduced dosages still offers a considerable degree of pituitary suppression, studies on dose adjustments in the use of triptorelin in ovarian stimulation in IVF are warranted.
Key words: GnRHa/gonadotrophin/IVF/pituitary/triptorelin
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  I. Ratbi, M. Legendre, F. Niel, J. Martin, J.-C. Soufir, V. Izard, B. Costes, C. Costa, M. Goossens, and E. Girodon Detection of cystic fibrosis transmembrane conductance regulator (CFTR) gene rearrangements enriches the mutation spectrum in congenital bilateral absence of the vas deferens and impacts on genetic counselling Hum. Reprod., May 1, 2007; 22(5): 1285 - 1291. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Baker, M. A. Wild, M. D. Hussain, R. L. Dunn, and T. M. Nett EVALUATION OF REMOTELY DELIVERED LEUPROLIDE ACETATE AS A CONTRACEPTIVE AGENT IN FEMALE ELK (CERVUS ELAPHUS NELSONI) J. Wildl. Dis., October 1, 2005; 41(4): 758 - 767. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. H. Yu Ng, C. Chi Wai Chan, O. S. Tang, W. Shu Biu Yeung, and P. Chung Ho Effect of pituitary downregulation on antral follicle count, ovarian volume and stromal blood flow measured by three-dimensional ultrasound with power Doppler prior to ovarian stimulation Hum. Reprod., December 1, 2004; 19(12): 2811 - 2815. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Grangeia, F. Niel, F. Carvalho, S. Fernandes, A. Ardalan, E. Girodon, J. Silva, L. Ferras, M. Sousa, and A. Barros Characterization of cystic fibrosis conductance transmembrane regulator gene mutations and IVS8 poly(T) variants in Portuguese patients with congenital absence of the vas deferens Hum. Reprod., November 1, 2004; 19(11): 2502 - 2508. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Baker, M. A. Wild, M. M. Connor, H. B. Ravivarapu, R. L. Dunn, and T. M. Nett GONADOTROPIN-RELEASING HORMONE AGONIST: A NEW APPROACH TO REVERSIBLE CONTRACEPTION IN FEMALE DEER J. Wildl. Dis., October 1, 2004; 40(4): 713 - 724. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Moldenhauer, G. C. Ostermeier, A. Johnson, M. P. Diamond, and S. A. Krawetz Diagnosing Male Factor Infertility Using Microarrays J Androl, November 1, 2003; 24(6): 783 - 789. [Full Text] [PDF]
|
|
|
|
 |
|
 V. Goossens, K. Sermon, W. Lissens, M. De Rycke, B. Saerens, A. De Vos, P. Henderix, H. Van de Velde, P. Platteau, A. Van Steirteghem, et al. Improving clinical preimplantation genetic diagnosis for cystic fibrosis by duplex PCR using two polymorphic markers or one polymorphic marker in combination with the detection of the {Delta}F508 mutation Mol. Hum. Reprod., September 1, 2003; 9(9): 559 - 567. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Kurinczuk Safety issues in assisted reproduction technology: From theory to reality--just what are the data telling us about ICSI offspring health and future fertility and should we be concerned? Hum. Reprod., May 1, 2003; 18(5): 925 - 931. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. N. Kolettis The Evaluation and Management of the Azoospermic Patient J Androl, May 1, 2002; 23(3): 293 - 305. [Full Text] [PDF]
|
|
|
|
|
|
R. N. Josserand, F. Bey-Omar, J. Rollet, H. Lejeune, D. Boggio, D. V. Durand, and I. Durieu Cystic fibrosis phenotype evaluation and paternity outcome in 50 males with congenital bilateral absence of vas deferens Hum. Reprod., October 1, 2001; 16(10): 2093 - 2097. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Dada, O. Salha, V. Allgar, and V. Sharma Utero-ovarian blood flow characteristics of pituitary desensitization Hum. Reprod., August 1, 2001; 16(8): 1663 - 1670. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.D. Prato, A. Borini, M.R. Trevisi, M.A. Bonu, E. Sereni, and C. Flamigni Effect of reduced dose of triptorelin at the start of ovarian stimulation on the outcome of IVF: a randomized study Hum. Reprod., July 1, 2001; 16(7): 1409 - 1414. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R.M.J. Janssens, C.B. Lambalk, J.P.W. Vermeiden, R. Schats, J.M. Bernards, L.T.M. Rekers-Mombarg, and J. Schoemaker Dose-finding study of triptorelin acetate for prevention of a premature LH surge in IVF: a prospective, randomized, double-blind, placebo-controlled study Hum. Reprod., November 1, 2000; 15(11): 2333 - 2340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.I. Lewis-Jones, M.R. Gazvani, and R. Mountford Cystic fibrosis in infertility: screening before assisted reproduction: Opinion Hum. Reprod., November 1, 2000; 15(11): 2415 - 2417. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Viville, S. Warter, J.-M. Meyer, C. Wittemer, M. Loriot, R. Mollard, and D. Jacqmin Histological and genetic analysis and risk assessment for chromosomal aberration after ICSI for patients presenting with CBAVD Hum. Reprod., July 1, 2000; 15(7): 1613 - 1618. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Cedrin-Durnerin, J.-M. Bidart, P. Robert, J.-P. Wolf, M. Uzan, and J.-N. Hugues Consequences on gonadotrophin secretion of an early discontinuation of gonadotrophin-releasing hormone agonist administration in short-term protocol for in-vitro fertilization Hum. Reprod., May 1, 2000; 15(5): 1009 - 1014. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U.-B. Wennerholm, C. Bergh, L. Hamberger, G. Westlander, M. Wikland, and M. Wood Obstetric outcome of pregnancies following ICSI, classified according to sperm origin and quality Hum. Reprod., May 1, 2000; 15(5): 1189 - 1194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Optimal use of infertility diagnostic tests and treatments Hum. Reprod., March 1, 2000; 15(3): 723 - 732. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G.T.M. Phillipson, O.M. Petrucco, and C.D. Matthews Congenital bilateral absence of the vas deferens, cystic fibrosis mutation analysis and intracytoplasmic sperm injection Hum. Reprod., February 1, 2000; 15(2): 431 - 435. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Boucher, I. Creveaux, G. Grizard, C. Jimenez, J. Hermabessiere, and B. Dastugue Screening for cystic fibrosis transmembrane conductance regulator gene mutations in men included in an intracytoplasmic sperm injection programme Mol. Hum. Reprod., June 1, 1999; 5(6): 587 - 593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O.H. Develioglu, B. Cox, J.P. Toner, S. Oehninger, and S.J. Muasher The value of basal serum follicle stimulating hormone, luteinizing hormone and oestradiol concentrations following pituitary down-regulation in predicting ovarian response to stimulation with highly purified follicle stimulating hormone* Hum. Reprod., May 1, 1999; 14(5): 1168 - 1174. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Lissens, K. Z. Mahmoud, E. El-Gindi, A. Abdel-Sattar, S. Seneca, A. Van Steirteghem, and I. Liebaers Molecular analysis of the cystic fibrosis gene reveals a high frequency of the intron 8 splice variant 5T in Egyptian males with congenital bilateral absence of the vas deferens Mol. Hum. Reprod., January 1, 1999; 5(1): 10 - 13. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Tournaye, T. Merdad, S. Silber, H. Joris, G. Verheyen, P. Devroey, and A. Van Steirteghem No differences in outcome after intracytoplasmic sperm injection with fresh or with frozen–thawed epididymal spermatozoa Hum. Reprod., January 1, 1999; 14(1): 90 - 95. [Abstract] [Full Text] [PDF]
|
|